These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 27405487)
1. Post-exposure treatment with whole inactivated H5N1 avian influenza virus protects against lethal homologous virus infection in mice. Hagan M; Ranadheera C; Audet J; Morin J; Leung A; Kobasa D Sci Rep; 2016 Jul; 6():29433. PubMed ID: 27405487 [TBL] [Abstract][Full Text] [Related]
2. A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice. Tian X; Landreth S; Lu Y; Pandey K; Zhou Y J Virol; 2021 Jan; 95(3):. PubMed ID: 33177192 [TBL] [Abstract][Full Text] [Related]
3. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses. Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P J Virol; 2017 May; 91(9):. PubMed ID: 28179535 [TBL] [Abstract][Full Text] [Related]
4. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice. Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133 [TBL] [Abstract][Full Text] [Related]
5. Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin. Sawai T; Itoh Y; Ozaki H; Isoda N; Okamoto K; Kashima Y; Kawaoka Y; Takeuchi Y; Kida H; Ogasawara K Immunology; 2008 Jun; 124(2):155-65. PubMed ID: 18205793 [TBL] [Abstract][Full Text] [Related]
6. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity. Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227 [TBL] [Abstract][Full Text] [Related]
7. Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice. Wong G; Qiu X; Ebihara H; Feldmann H; Kobinger GP J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S435-42. PubMed ID: 26022441 [TBL] [Abstract][Full Text] [Related]
8. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951 [TBL] [Abstract][Full Text] [Related]
9. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia. Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232 [TBL] [Abstract][Full Text] [Related]
11. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines. Jang YH; Jung EJ; Byun YH; Lee KH; Lee EY; Lee YJ; Seong BL Vaccine; 2013 Jul; 31(33):3339-46. PubMed ID: 23742997 [TBL] [Abstract][Full Text] [Related]
13. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice. Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202 [TBL] [Abstract][Full Text] [Related]
14. Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine. Nakayama M; Shichinohe S; Itoh Y; Ishigaki H; Kitano M; Arikata M; Pham VL; Ishida H; Kitagawa N; Okamatsu M; Sakoda Y; Ichikawa T; Tsuchiya H; Nakamura S; Le QM; Ito M; Kawaoka Y; Kida H; Ogasawara K PLoS One; 2013; 8(12):e82740. PubMed ID: 24376571 [TBL] [Abstract][Full Text] [Related]
15. IgG antibodies mediate protective immunity of inactivated vaccine for highly pathogenic H5N1 influenza viruses in ferrets. Shin JS; Kim HS; Cho SH; Seo SH Viral Immunol; 2010 Jun; 23(3):321-7. PubMed ID: 20565295 [TBL] [Abstract][Full Text] [Related]
16. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy. Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631 [TBL] [Abstract][Full Text] [Related]
17. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Ninomiya A; Imai M; Tashiro M; Odagiri T Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015 [TBL] [Abstract][Full Text] [Related]
18. Protection of pregnant mice, fetuses and neonates from lethality of H5N1 influenza viruses by maternal vaccination. Hwang SD; Shin JS; Ku KB; Kim HS; Cho SW; Seo SH Vaccine; 2010 Apr; 28(17):2957-64. PubMed ID: 20188684 [TBL] [Abstract][Full Text] [Related]
19. Comparison of protection against H5N1 influenza virus in mouse offspring provided by maternal vaccination with HA DNA and inactivated vaccine. Zhang F; Fang F; Chang H; Peng B; Wu J; Chen J; Wang H; Chen Z Arch Virol; 2013 Jun; 158(6):1253-65. PubMed ID: 23385327 [TBL] [Abstract][Full Text] [Related]
20. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]